Predicting Drug-Target Interactions Using Drug-Drug Interactions

被引:10
作者
Kim, Shinhyuk [1 ]
Jin, Daeyong [1 ]
Lee, Hyunju [1 ]
机构
[1] Gwangju Inst Sci & Technol, Sch Informat & Commun, Kwangju, South Korea
关键词
PROTEIN; DATABASE; IDENTIFICATION; NETWORKS; MODELS;
D O I
10.1371/journal.pone.0080129
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Computational methods for predicting drug-target interactions have become important in drug research because they can help to reduce the time, cost, and failure rates for developing new drugs. Recently, with the accumulation of drug-related data sets related to drug side effects and pharmacological data, it has became possible to predict potential drug-target interactions. In this study, we focus on drug-drug interactions (DDI), their adverse effects (DDIAE) and pharmacological information (DDIPharm), and investigate the relationship among chemical structures, side effects, and DDIs from several data sources. In this study, DDIPharm data from the STITCH database, DDIAE from drugs.com, and drug-target pairs from ChEMBL and SIDER were first collected. Then, by applying two machine learning approaches, a support vector machine (SVM) and a kernel-based L1-norm regularized logistic regression (KL1LR), we showed that DDI is a promising feature in predicting drug-target interactions. Next, the accuracies of predicting drug-target interactions using DDI were compared to those obtained using the chemical structure and side effects based on the SVM and KL1LR approaches, showing that DDI was the data source contributing the most for predicting drug-target interactions.
引用
收藏
页数:12
相关论文
共 36 条
[1]  
[Anonymous], 2004, INT C MACH LEARN
[2]   The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective [J].
Bjornsson, TD ;
Callaghan, JT ;
Einolf, HJ ;
Fischer, V ;
Gan, L ;
Grimm, S ;
Kao, J ;
King, SP ;
Miwa, G ;
Ni, L ;
Kumar, G ;
McLeod, J ;
Obach, SR ;
Roberts, S ;
Roe, A ;
Shah, A ;
Snikeris, F ;
Sullivan, JT ;
Tweedie, D ;
Vega, JM ;
Walsh, J ;
Wrighton, SA .
JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (05) :443-469
[3]   Supervised prediction of drug-target interactions using bipartite local models [J].
Bleakley, Kevin ;
Yamanishi, Yoshihiro .
BIOINFORMATICS, 2009, 25 (18) :2397-2403
[4]   Drug target identification using side-effect similarity [J].
Campillos, Monica ;
Kuhn, Michael ;
Gavin, Anne-Claude ;
Jensen, Lars Juhl ;
Bork, Peer .
SCIENCE, 2008, 321 (5886) :263-266
[5]   Structure-based maximal affinity model predicts small-molecule druggability [J].
Cheng, Alan C. ;
Coleman, Ryan G. ;
Smyth, Kathleen T. ;
Cao, Qing ;
Soulard, Patricia ;
Caffrey, Daniel R. ;
Salzberg, Anna C. ;
Huang, Enoch S. .
NATURE BIOTECHNOLOGY, 2007, 25 (01) :71-75
[6]   Genome scale enzyme-metabolite and drug-target interaction predictions using the signature molecular descriptor [J].
Faulon, Jean-Loup ;
Misra, Milind ;
Martin, Shawn ;
Sale, Ken ;
Sapra, Rajat .
BIOINFORMATICS, 2008, 24 (02) :225-233
[7]  
Faulon JL, 2012, SIGNATURE MOL DESCRI
[8]   Evaluation of the utility of homology models in high throughput docking [J].
Ferrara, Philippe ;
Jacoby, Edgar .
JOURNAL OF MOLECULAR MODELING, 2007, 13 (08) :897-905
[9]   ChEMBL: a large-scale bioactivity database for drug discovery [J].
Gaulton, Anna ;
Bellis, Louisa J. ;
Bento, A. Patricia ;
Chambers, Jon ;
Davies, Mark ;
Hersey, Anne ;
Light, Yvonne ;
McGlinchey, Shaun ;
Michalovich, David ;
Al-Lazikani, Bissan ;
Overington, John P. .
NUCLEIC ACIDS RESEARCH, 2012, 40 (D1) :D1100-D1107
[10]   VOLUME CHANGES IN PROTEIN EVOLUTION [J].
GERSTEIN, M ;
SONNHAMMER, ELL ;
CHOTHIA, C .
JOURNAL OF MOLECULAR BIOLOGY, 1994, 236 (04) :1067-1078